Categories: Wire Stories

Enfusion Launches New Features to Address Emerging OEMS Adoption Across Asset Management Industry

Industry increasingly turning to SaaS-based technologies to facilitate multi-asset operations

NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-native SaaS solutions for investment managers, released more than 100 enhancements and new features for its Order and Execution Management System (OEMS) in Q1 2022, as the asset management community increasingly shifts towards solutions that address the complexities associated with managing sophisticated daily order flow.

Asset managers globally are faced with fee compression, market volatility, and the need to diversify their suite of investment product offerings to meet client demand. Many are launching new investment products, often multi-asset, where the focus is outside of their core strategies. As they make this shift, like their hedge fund counterparts, new technologies including SaaS-based Order and Execution Management (�OEMS”) Systems have gained traction. As reported in Enfusion’s Q1 2022 earnings, Enfusion OEMS bookings accounted for 46% of total bookings in Q1 compared to an average of 25% in the same period last year (+21%).

Enfusion is one seam-free, front-to-back office platform which is built natively as multi-tenant SaaS. It includes a Portfolio Management System, OEMS, General Ledger Accounting System, and Analytics System. Managers can deploy the full platform or individual modules. Enfusion offers its platform across desktop, web, and mobile.

“Enfusion has been a valued partner as we’ve expanded into new asset classes,” said Sean Greenwaldt, Director of Trading, Crabel Capital Management. “Their consultative approach gave us the confidence to entrust Enfusion with this vital business function. The highly functional multi-asset OMS solution that was delivered has allowed us to optimize the output from critical internal resources and has facilitated our firm’s growth in an efficient fashion.”

Based on the continued feedback loop from its clients, Enfusion has rolled out new OEMS features in Q1 which are also attractive to the greater investment community, including:

  • Expanded Fixed Income Support: Users benefit from improved allocation support, RFQ entry and storage, and API feature support.
  • Improved Broker Defaults: Users have the ability to automatically assign counterparties to orders at order generation for non-listed products, which reduces manual selection errors.
  • CDX Routing Schemes: Users can create execution schemes for CDX orders allowing for quick transmission to execution venues.
  • Expanded IRS and CDX order functionality: Enhanced IRS and CDX order tickets allow for quick, intuitive order entry and staging as well as integration with the RFQ process to maintain best execution audit history.

“Technology solutions for investment managers are no longer pigeonholed for specific manager styles, opening the door for asset managers to tap into solutions that have traditionally been thought of as ‘hedge fund’ specific,” said Thomas Kim, Chief Executive Officer at Enfusion. “Asset managers are seeking an approach to order and execution management that allows them to do more, at scale, and do it more easily. Between the continued feedback we receive from those across the industry, and the scalable SaaS based nature of our business, we can easily roll out upgrades and enhancements that better the experience without disrupting it, as the business of asset management evolves.”

ABOUT ENFUSION

Enfusion’s investment management software-as-a-service (SaaS) platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one, cloud-native system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility, and powering growth. Enfusion partners with 750+ investment managers from 10 global offices spanning four continents.

Source: Enfusion, Inc.

Source Code: ENFN-IR

ENFN-CORP

Contacts

Investors

Ignatius Njoku

Ignatius.njoku@enfusion.com

Media

Prosek Partners

pro-enfusion@prosek.com

Alex

Recent Posts

Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics

Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and…

29 mins ago

FourKites Signs on as Collaborator to Consortium of Supply Chain Leaders Working to Streamline Scheduling Technology Across the Logistics Industry

FourKites is the first real-time visibility platform participating in the SSC CHICAGO--(BUSINESS WIRE)--Leading real-time supply…

54 mins ago

Hopewind on Bloomberg New Energy Finance Tier 1 List and Only Chinese Inverter Company on Intersolar / Smarter E Award Short-list

ALMERE, Netherlands--(BUSINESS WIRE)--Hopewind (SHANGHAI STOCK EXCHANGE Code: 603063) has been officially nominated for the 2024…

56 mins ago

Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare Company

TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Corp. (TOKYO:3407) today announces that it…

57 mins ago

Kenanga Investment Bank Posts 119% Jump in Net Profit, Revenue Rises to RM204.2 million for 1Q 2024

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 28 May 2024 - Kenanga Investment Bank…

2 hours ago